CHRNA7 and glioblastoma: Enhancing α7 nAChR activity can effectively enhance attention and neural cell damage resistance [20], whereas inhibitors targeting α7 nAChRs have the potential to treat glioblastoma and have certain research and development prospects in clinical applications [21].